Trial reportThe American journal of medicine1989
Summary of safety and efficacy data on a yeast-derived hepatitis B vaccine.
Trial report in The American journal of medicine, 1989. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 4 syntheses or guidelines pooled it, 205 citations in OpenAlex.
- Sexually Transmitted Infections Treatment Guidelines, 2021.MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports · 2021Guideline
- Prevention of Hepatitis B Virus Infection in the United States: Recommendations of the Advisory Committee on Immunization Practices.MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports · 2018Guideline
- Hepatitis B vaccination during pregnancy for preventing infant infection.The Cochrane database of systematic reviews · 2014Pooled it
- Immune response of hepatitis B vaccine among persons with diabetes: a systematic review of the literature.Diabetes care · 2012Pooled it
- Trial
- Trial
- Article
- Canadian Association of Gastroenterology Clinical Practice Guideline for Immunizations in Patients With Inflammatory Bowel Disease (IBD)-Part 2: Inactivated Vaccines.Journal of the Canadian Association of Gastroenterology · 2021Review
- The effect of universal infant vaccination on the prevalence of hepatitis B immunity in adult solid organ transplant candidates.Journal of viral hepatitis · 2021Article
- Variations in Hepatitis B Vaccine Series Completion by Setting Among Adults at Risk in West Virginia.American journal of preventive medicine · 2020Article
- Article
- Article
- Hepatitis B immunization for indigenous adults, Australia.Bulletin of the World Health Organization · 2016Article
- Antibody response to revaccination among adult non-responders to primary Hepatitis B vaccination in China.Human vaccines & immunotherapeutics · 2015Article
- Strategy vaccination against Hepatitis B in China.Human vaccines & immunotherapeutics · 2015Review
- Chronic hepatitis B in 2014: great therapeutic progress, large diagnostic deficit.World journal of gastroenterology · 2014Review
- The potential of 1018 ISS adjuvant in hepatitis B vaccines: HEPLISAV™ review.Human vaccines & immunotherapeutics · 2013Review
- Article
- Epidemiology and prevention of hepatitis B virus infection.The Korean journal of hepatology · 2011Review
- Hepatitis B vaccination among a national sample of gay and bisexual men.Sexually transmitted diseases · 2011Article
Corrections and comments
- Commented on by
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Recombinant deoxyribonucleic acid technology has permitted the development of a vaccine from the hepatitis B surface antigen expressed in genetically manipulated yeast cells. Clinical trials with the vaccine were started in February 1984 and, to date, have involved more than 12,500 persons. The vaccine has been shown to be safe, well tolerated, and immunogenic in healthy persons of all ages and in special target groups likely to require vaccination. The vaccine's protective efficacy has been established in three groups at high risk for hepatitis B infection--homosexual men, institutionalized mentally handicapped patients, and neonates of mothers who are chronic carriers. Production of this vaccine on a large scale should make it less expensive than plasma-derived vaccines and thus broaden the indications for vaccination.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.